CHICAGO—Delia Chiaramonte, MD, associate director of education at the Center for Integrative Medicine at the University of Maryland School of Medicine in Baltimore, presented the newest thinking on pain to a gathering of rheumatologists at the ACR’s State-of-the-Art Clinical Symposium in April. She began by explaining that pain is more than nociception. Nociception stimulates nerves to…
Hepatitis Virus, Rheumatic Disease Connection Explored
CHICAGO—Leonard H. Calabrese, DO, professor of medicine at Cleveland Clinic in Ohio, presented on emerging concepts of viral infections and rheumatic disease at the ACR’s State-of-the-Art Clinical Symposium in April. “We are at a pivotal point in rheumatology in understanding the relationship between viruses and rheumatic disease,” began Dr. Calabrese. “It’s a very exciting time.” Dr. Calabrese…
Diagnosis, Treatment Updates for Lyme Arthritis
CHICAGO—A clustering of cases in Lyme, Conn., in 1975 led to the discovery of Lyme disease. Allen C. Steere, MD, professor of medicine at Harvard Medical School in Boston, investigated that outbreak, and he shared his knowledge of Lyme disease with rheumatologists gathered at the ACR’s State-of-the-Art Clinical Symposium in April. He explained that Lyme arthritis…
Myositis AutoantibodiesTriggered by Statins
CHICAGO—On a Saturday morning in Chicago, Chester V. Oddis, MD, director of the Myositis Center at the University of Pittsburgh, explained to a crowded room of about 500 rheumatologists attending the ACR’s State-of-the-Art Clinical Symposium in April how best to use myositis autoantibodies in clinical care. He began with an overview of the different types of…
Latest Research on Cutaneous Vasculitis Diagnosis, Treatment
CHICAGO—Warren Piette, MD, professor of dermatology at Rush University Medical Center, Chicago, updated rheumatologists on the topic of cutaneous vasculitis at the ACR’s State-of-the-Art Clinical Symposium in April. He began by explaining that the current vasculitis criteria developed by the ACR in 1990 and the Chapel Hill Consensus Conference (CHCC) in 1994 are inadequate to incorporate…
Advancements in Diagnosis, Treatment for Antiphospholipid Syndrome
CHICAGO—Doruk Erkan, MD, MPH, a rheumatologist at the Hospital for Special Surgery and Weill Cornell Medicine in New York City, described recent developments in the field of antiphospholipid syndrome (APS) to the rheumatologists gathered for the ACR’s State-of-the-Art Clinical Symposium in April. He introduced APS as a “field with limited data and lots of controversies,” although,…
Amyloidosis Is Often Underdiagnosed, Undertreated
CHICAGO—Caryn A. Libbey, MD, clinical associate professor of medicine at Boston University School of Medicine, described the evolving in our understanding of amyloid at the ACR’s State-of-the-Art Clinical Symposium in April. Amyloidosis is a rare disease that is often underdiagnosed and undertreated. “Even though this disease has been around for 150 years, I still consider it…
EULAR Releases 2016 Recommendations on RA Management
Management of rheumatoid arthritis (RA) is complex. The ever-expanding availability of new drugs requires that rheumatologists and patients constantly consider treatment strategies and targets aimed at both disease control and symptom relief while remaining cognizant of the increasing high cost of emerging medications. Given such complexity, guidelines to inform rheumatologists about the most recent developments…
Juvenile-Onset Arthritis Bodes Worse Pregnancy Outcomes
NEW YORK (Reuters Health)—Women with a diagnosis of juvenile idiopathic arthritis (JIA) are at increased risk of pregnancy complications, according to Swedish researchers. As Dr. Katarina Remaeus told Reuters Health by email, “In our cohort study . . . we found an association with adverse pregnancy outcomes including preterm birth, induction of labor and delivery…
RA Treatments Show Mixed Results
Highlights from the 2017 EULAR Congress MADRID—The anti-IL6 “nanobody,” vobarilizumab, produced mixed results when used with methotrexate (MTX), compared with MTX and placebo, according to results of a 24-week, double-blind Phase 2b study of patients with rheumatoid arthritis (RA), which were presented in an abstract session at the Annual European Congress of Rheumatology (EULAR). The…
- « Previous Page
- 1
- …
- 163
- 164
- 165
- 166
- 167
- …
- 319
- Next Page »